evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,133 questions · 1,153 findings · 36 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 407 · 35.3%GRADE not reported 90 · 7.8%Very low 183 · 15.9%Low 209 · 18.1%Moderate 211 · 18.3%High 53 · 4.6%

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day

Recurrence · People with American cutaneous and mucocutaneous leishmaniasis

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).

1 finding from 1 review

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).

1 finding from 1 review

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).

1 finding from 1 review

IFN‐α + PUVA vs PUVA

Improvement of quality of life · people with mycosis fungoides

The review found no eligible studies for this question.

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks) · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in common adverse effects ‐ Photosensitivity (Time point of… compared with PUVA alone (low certainty).

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Complete response · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in complete response (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Objective response rate · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in objective response rate (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).

1 finding from 1 review

IFN‐α + acitretin vs IFN‐α + PUVA

Adverse event (flu‐like symptoms) · people with mycosis fungoides

IFN‐α + acitretin showed no clear difference in common adverse effects ‐ Flu‐like symptoms (Time point of… compared with IFN‐α + PUVA (low certainty).

1 finding from 1 review

IFN‐α + acitretin vs IFN‐α + PUVA

Complete response · people with mycosis fungoides

IFN‐α + acitretin may leads to lower complete response (Time point of measurement: up to 48 weeks or… compared with IFN‐α + PUVA (low certainty).

1 finding from 1 review